Patent · US Active

Sustained release aminopyridine composition

US8007826B2 · kind B2 · utility

11Cited by

15References

41Claims

0Family size

Assignee

Acorda Therapeutics, Inc. · US

Inventors

Andrew R. Blight · Pontefract, GB
Ron Cohen · Ramat HaSharon, IL

Key dates

Filing date	Dec 13, 2004
Grant date	Aug 30, 2011
Priority date	—
Expiry date	May 26, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.